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Abstract
Background: Tanner staging (TS), a five-stage classification indicating no breast tissue (TS1) to full breast development
(TS5), is used both in health research and clinical care to assess the onset of breast development (TS2) and duration in
each stage. Currently, TS is measured both visually and through palpation but non-invasive methods will improve
comparisons across settings.
Methods: We used optical spectroscopy (OS) measures from 102 girls at the Ontario site of the LEGACY girls
study (average age 12 years, range 10.0–15.4 years) to determine whether breast tissue optical properties map
to each TS. We further examined whether these properties differed by age, body mass index (BMI), and breast
cancer risk score (BCRS) by examining the major principal components (PC).
Results: Age and BMI increased linearly with increasing TS. Eight PCs explained 99.9% of the variation in OS
data. Unlike the linear increase with age and BMI, OS components had distinct patterns by TS: the onset of
breast development (TS1 to TS2) was marked by elevation of PC3 scores indicating an increase in adipose tissue
and decrease in signal from the pectoral muscle; transition to TS3 was marked by elevation of PC6 and PC7 and
decline of PC2 scores indicating an increase in glandular or dense tissue; and transition to TS4+ by decline of PC2
scores representing a further increase in glandular tissue relative to adipose tissue. Of the eight PCs, three component
scores (PC4, PC5, and PC8) remained in the best-fitting model of BCRS, suggesting different levels of collagen in the
breast tissue by BCRS.
Conclusions: Our results suggest that serial measures of OS, a non-invasive assessment of breast tissue characteristics,
can be used as an objective outcome that does not rely on visual inspection or palpation, for studying drivers of breast
development.
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Background
Breast cancer (BC) incidence is increasing in women under
age 40 years in the US [1] and is increasingly common
worldwide in women under age 50 years [2, 3]. Decline in
the age of breast development [4] may account for some of
the change. Age of menarche, a long-established risk factor
for breast cancer, has been relatively stable in recent de-
cades [5]. As the interval between early breast development
and the age at menarche (referred to as pubertal tempo)
when the breast may be more susceptible to carcinogens
has widened, it is essential to have other measures of
pubertal development [6]. Height, age at breast devel-
opment, age at menarche, and increased tempo were
each independently associated with an increase in BC
risk in a large prospective cohort study [7]. Compared
with height and age at menarche, age at breast develop-
ment has been more challenging to determine.
Breast development is often assessed using Tanner stages
(TS), which is routinely used in clinical evaluation. TS
range from TS1 to TS5, and are separately evaluated
for breast and pubic hair. We focus this paper on breast
TS with TS1 referring to no breast development, TS2 as
the first appearance of breast buds, TS3 where the areola
and breast are larger than just buds but the areola does
not stick out away from the breast, TS4 where the nipple
is raised above the breast, and TS5 the mature breast.
Tanner stage is generally assessed by a clinician using
visual inspection followed with palpation, but can also be
evaluated by self-reporting or maternal reporting using
drawings of TS with explanatory text [8]. TS reporting by
parents or self-reporting has been less reliable and valid
compared with clinician reports, with parents more
accurate reporters of TS in children before age 11 years
and children more accurate reporters after age 11 [9].
Breast development can also be tracked through imaging
methods, although most imaging methods such as dual-
energy x-ray absorptiometry, magnetic resonance imaging
or mammography are either too expensive to use rou-
tinely in young girls and/or involve exposing the breast
to ionizing radiation. Breast tissue composition is associated
with mammographic breast density (MBD), which repre-
sents the connective and glandular versus the adipose tissue
fraction [10–12]. The tissue components giving rise to
MBD have distinct optical absorption spectra, which
led to the development of optical spectroscopy (OS)
methods to examine breast tissue composition using
visible and near infrared light. OS has been shown to
identify women of mammographic screening age hav-
ing >75% MBD [13] and who are at elevated risk of
BC, with sensitivity and specificity >0.9 [14, 15]. Studies in
younger women (31–40 years of age) showed strong
associations with parity [16], another well-established BC
risk factor. Here we present an extension of the OS
technique adapted for the developing breast of girls
ages ≥10 years, to demonstrate the utility of this method
to detect breast development TS, adjusting for age, BMI,
and breast cancer risk score (BCRS). We further examined
whether BCRS was associated with OS components.
Methods
Study population
The participants in this study were from the Ontario site
of the LEGACY girls study [17], an NCI-funded pro-
spective cohort of 1040 girls enrolled at ages 6–13 years
at five study sites in the US and Canada. Half of the girls
come from families with positive BC history (BCFH+)
defined as having at least one first or second degree rela-
tive diagnosed with BC. Girls without a breast cancer
family history (BCFH-) had no first or second degree
relative with BC. All participating institutions obtained
Institutional Review Board approval (for more details see
[17] and www.legacygirlstudy.org).
Of the girls from the Ontario site who were 10 years
and older and who were invited to participate in the OS
study, 93% accepted and completed baseline and follow-up
measures. There were 105 Ontario girls initially eligible for
this pilot study, with 102 complete datasets for analysis.
OS instrumentation and data preparation for final analysis
The OS approach was similar to that previously de-
scribed in adult women [18, 19] except for using light
diffusely reflected from the tissue rather than trans-
mitted through the breast, as TS1 to TS3 do not pro-
vide sufficient tissue to place the optical fiber bundles
at opposite sides of the breast for transmission experi-
ments [20, 21]. Reflectance quantification covered the
635–1060 nm spectral range. A 5-mm fiber bundle
delivered broadband light from a halogen lamp to the
skin surface and a 3-mm fiber bundle collected the diffuse
reflected photons guiding it to the holographic transmission
spectrophotometer (PPO, Kitchener, ON, Canada) with a
cooled 256 × 1440 pixel CCD (Photometrics, NJ, USA).
A black flexible template (shown in Additional file 1:
Figure S1A), provided reproducible inter-optode distances
and absorbed all photons reaching the surface. The partici-
pant was in the supine position and optical measurements
were executed at four quadrants (Additional file 1:
Figure S1B), superior, lateral, inferior, and medial on
each breast, resulting in eight diffuse reflectance spectra
per participant. The light source irradiance (approximately
180 mWcm−2) equals approximately twice the noontime
solar exposure during the summer solstice in Boston, MA,
USA, but does not contain UV or blue spectral compo-
nents. Exposure times were 2–80 sec per spectrum.
Spectra were corrected for exposure time and dark signal,
and a 7-point boxcar smoothing algorithm was applied
followed by a cubic spline interpolation to sample spectra
at 1 nm increments. Spectra were corrected for variations
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in the instrument throughput using a high albedo reflection
standard, resulting in effective light attenuation spectra.
Corrected spectra were mean-centered for principal com-
ponent analysis (PCA). While two inter-optode distances
(1.5 and 3 cm) were used, the short distance at times
resulted in suspect detector saturation effects and was not
further considered in this analysis; thus, 840 spectra were
used to determine orthogonal PCA spectra reducing the
dimensionality of information in each original spectrum.
The eight first component vectors (PC1–PC8) (see
Additional file 1: Figure S2) represent 99.99% of the
variation seen in the complete dataset. Each principal
component (PC) spectrum represents different optical
tissue features, including light scattering by cellular
and structural components, and absorption dominated
by the five main breast tissue components (water, lipid,
oxy-hemoglobin (HbO2), deoxy-hemoglobin (Hb), and
collagen) and residual absorption by yet unidentified
chromophores. As the breast develops homogenously
bilaterally and only tissue average properties are sought,
each PC score was averaged over both breasts resulting in
an OS dataset comprising 105 girls, each having one score
for each of the eight principal components (PC1–PC8).
Breast cancer risk score
We calculated a continuous probability score reflecting
each girl’s estimated absolute lifetime risk of breast cancer.
We estimated the BCRS based on available detailed
pedigree data, allowing us to calculate a risk score using
the breast and ovarian analysis of disease incidence and
carrier estimation algorithm (BOADICEA) [22–24].
Statistical methods
Complete data on age, body mass index (BMI) collected
through clinical measures, Tanner breast stage assessed
by a guardian, and BCRS were available for 102 of the
105 girls. Due to a small sample of girls in the TS5 group
(n = 6) and the fact that some adolescent girls go directly
from TS3 to TS5 without a TS4 or do not progress to
TS5, we combined TS4 and TS5 for the analyses.
We used descriptive statistics to summarize the data.
Analysis of variance (ANOVA) and univariate logistic
regression were performed to identify covariates from
PC1–PC8 scores, age, BMI and BCRS that predict breast
stage. We also incorporated random forest analysis to
examine the influence of all covariates together in the
prediction, as multivariate logistic regression predictions
are not reliable in a small dataset with many covariates.
The features selected were used in multivariate logistic
regression models. Linear discriminant analysis (LDA)
with 60% of the data used as a training set and the rest
used as a test set was applied to measure the predictive
ability. We also examined the ability of OS measure-
ments to predict BCRS. The best predictive model was
selected by Akaike’s information criteria (AIC) [25]. Before
conducting the above analyses, each PC score and BCRS
were rescaled by dividing by the corresponding interquar-
tile range for meaningful interpretation of the results.
Correlation, regression, ANOVA and LDA analyses were
performed using SAS 9.1 software (SAS Institute, Inc.) and
the other analyses and plots were achieved using R statis-
tical software, version 2.15.0 (http://www.r-project.org).
Results
Study cohort characteristics
Table 1 summarizes descriptive statistics for the cohort.
The average age of the girls was 12.0 years with a range
of 10.0–15.4 years. The average BMI was 18.6 with a
range of 12.5–33.2. The average BCRS was 15% lifetime
risk with a range of 11–30%.
The association between OS measurements and breast TS
Eight PCs explained >99.9% of the variation in OS.
Table 2, summary statistics (Additional file 2: Table S1A)
and Additional file 1: Figure S3A show the association
between age, BMI, and each OS PC with breast stage
(TS1, TS2, TS3, and TS4). Breast stage increased with
increasing age and BMI, as expected (P < 0.01). Unlike
Table 1 Characteristics of the cohort
Characteristic Number Percentage
Age (years)
10 to <12 63 61.8
12 to <14 25 24.5
> = 14 14 13.7
Mean age = 12.03, SD = 1.43, minimum = 10.01, maximum= 15.38
BMI
10 to <15 6 5.9
15 to <20 71 69.6
20 to <25 19 18.6
25+ 6 5.9







Breast cancer risk category
BCRS <0.12 41 40.2
0.12 <= BCRS <0.2 46 45.1
BCRS > = 0.2 15 14.7
Mean BCRS = 0.15, SD = 0.05, minimum= 0.11, maximum= 0.30
BMI body mass index, BCRS breast cancer risk score
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the linear increase with age and BMI, OS components
had distinct patterns by TS: the onset of breast develop-
ment (TS1 to TS2) was marked by elevation of PC3
scores; transition to TS3 was marked by elevation of
PC6 and PC7 and decline of PC2 scores; and transition
to TS4+ by the decline of PC2 scores.
Variable importance plots (Additional file 1: Figure S4A)
by random forest feature selection confirmed some of
these factors as important predictors in classifying girls
into four breast stages. The results of the comparison of
T2 vs. T1 summarized in Table 3 show that the PC3 score
significantly distinguished T2 from T1 (P = 0.002). Table 4
shows the difference between TS3–TS5 compared
with TS1 − TS2 and supports the elevation in PC6
and PC7 and a decrease in PC2 scores with TS3+ as
summarized in Table 2. Other supporting results are
given in Additional file 2: Table S1B, Additional file
1: Figures S3B and S4B. This decrease in PC2 was
also seen in the comparison of TS4–TS5 vs. TS1–
TS3 (Table 5). However, the other patterns observed
in Table 2 with an increase in PC4 and PC5 and a
decrease in PC1 scores were not seen in the logistic
regression models.
In the LDA analysis to examine the predictive power
of the model (Table 4, multivariate analysis) of OS PC in
Table 2 Association between breast Tanner stage and age, BMI,
BCRS, and OS principal component scores
Breast Tanner stage
Predictor 1 2 3 4
Mean Mean Mean Mean P value
Age 11.05 11.19 12.32 13.58 <0.01
BMI 16.50 17.31 18.90 19.70 <0.01
BCRS 1.70 2.04 1.80 1.88 0.23
PC1 0.190 0.001 0.102 −0.368 0.26
PC2 0.33 0.31 −0.23 −0.41 <0.01
PC3 −0.62 0.11 0.15 0.10 <0.01
PC4 0..04 −0.04 −0.03 0.14 0.84
PC5 −0.07 −0.08 0.01 0.22 0.60
PC6 −0.34 −0.27 0.28 0.24 <0.01
PC7 −0.23 −0.20 0.20 0.24 0.06
PC8 −0.12 0.05 −0.01 0.25 0.60
BMI body mass index, BCRS breast cancer risk score, PC principal component,
OS optical spectroscopy
Table 3 Multinomial logistic regression results for TS2 versus
TS1 breast stage prediction
Univariate Multivariate
Model P value OR CI (95%) P value OR CI (95%)
Age 0.5904 1.23 0.58 2.62 0.9826 0.99 0.38 2.59
BMI 0.2044 1.22 0.90 1.66 0.6659 0.92 0.61 1.37
BCRS 0.0783 2.90 0.89 9.50
PC1 0.4766 0.77 0.38 1.57
PC2 0.8733 0.91 0.27 3.01 0.1928 0.25 0.03 2.00
PC3 0.0017 5.47 1.89 15.79 0.0019 12.64 2.55 62.67
PC4 0.6967 0.84 0.35 2.01
PC5 0.9609 0.98 0.45 2.16
PC6 0.7464 1.16 0.47 2.87 0.2224 2.00 0.66 6.06
PC7 0.8855 1.06 0.47 2.38
PC8 0.5474 1.24 0.62 2.49
TS Tanner stage, BMI body mass index, BCRS breast cancer risk score, PC
principal component
Table 4 Binary logistic regression results for late (TS3–TS5) vs.
early (TS1–TS2) breast stage prediction
Univariate Multivariate
Model P value OR CI (95%) P value OR CI (95%)
Age <0.0001 3.32 2.03 5.42 0.1766 1.52 0.83 2.77
BMI <0.0001 1.66 1.31 2.10 0.0020 1.59 1.19 2.14
BCRS 0.3858 0.74 0.37 1.46
PC1 0.7848 0.94 0.61 1.45
PC2 <0.0001 0.12 0.05 0.29 0.0011 0.08 0.02 0.37
PC3 0.0513 1.78 1.00 3.17
PC4 0.7290 1.11 0.63 1.96
PC5 0.2866 1.32 0.79 2.20
PC6 0.0027 2.42 1.36 4.32 0.0371 2.47 1.06 5.67
PC7 0.0078 2.25 1.24 4.09 0.0252 2.74 1.13 6.64
PC8 0.5248 1.17 0.72 1.91
TS Tanner stage, BMI body mass index, BCRS breast cancer risk score, PC
principal component
Table 5 Binary logistic regression results for TS4–TS5 vs. TS1–TS3
breast stage prediction
Univariate Multivariate
Model P value OR CI (95%) P value OR CI (95%)
Age <0.0001 2.65 1.75 4.01 0.0129 1.86 1.14 3.04
BMI 0.0002 1.54 1.23 1.93 0.0011 1.55 1.19 2.01
BCRS 0.9185 0.96 0.43 2.14
PC1 0.4113 0.81 0.49 1.34
PC2 0.0012 0.23 0.09 0.55 0.0474 0.26 0.07 0.99
PC3 0.3811 1.34 0.69 2.61
PC4 0.4040 1.33 0.68 2.63
PC5 0.2123 1.46 0.81 2.65
PC6 0.3430 1.31 0.75 2.31
PC7 0.1585 1.58 0.84 3.00
PC8 0.2050 1.52 0.80 2.92
TS Tanner stage, BMI body mass index, BCRS breast cancer risk score, PC
principal component
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classifying girls into early stage (TS1–TS2) or late stage
(TS3–TS5), the predictors in the test set of data had a
reasonable multivariate normal distribution, which was
the underlying assumption in LDA analysis. In the train-
ing set of data (n = 62), 56/62 (90%) of girls were classi-
fied correctly by the discriminant function obtained
from the predictions. The cross-validated error rate was
11%. In the test set of data (n = 40), the discriminant
function correctly classified 34/40 (85%) of girls (data
not shown). Further, a receiver operator characteristic
(ROC) area under the curve (AUC) of 0.94 confirmed
that the accuracy of the predictor obtained by age, BMI,
PC2, PC6, and PC7 was able to distinguish the early
from the late breast stage (Fig. 1).
The association between OS measurements and BCRS
The scores of three OS components (PC4, PC5, and
PC8) together best predicted BCRS, even after accounting
for age and BMI. Additional file 2: Table S2A summarizes
the correlation analysis and scatter plots are given in
Additional file 1: Figure S5. These and simple linear re-
gression analysis (Table 6) showed that scores PC4 and
PC8 are negatively correlated with BCRS, indicating
that girls in the 75th percentile of these variables tend
to have a lower BCRS. Multivariate regression analysis
showed that age and BMI are not associated with
BCRS.
The PC5 score was slightly positively correlated with
BCRS, indicating a trend toward higher PC5 scores
being associated with a higher BCRS. The best model
found by subset selection in multiple linear regression
models (Table 6) showed that PC4, PC5, and PC8 scores
together best predict BCRS. The BCRS of a girl at the
75th scores percentile of PC4 or PC8 was expected to be
about 0.011 or 0.015 lower than that of a girl at the 25th
percentile of PC4 or PC8 respectively. BCRS for girls
with the 75th percentile of PC5 was expected to be
about 0.009 higher than girls in the 25th percentile of
PC5. We re-examined the association between OS
measurements and BCRS in the subgroup of TS3–TS5.
Correlation analysis (Additional file 2: Table S2B) and
simple linear regression analysis (Table 7) showed that
scores PC4 and PC8 remained negatively correlated with
BCRS, indicating that those with higher scores in these
variables tend to have lower BC risk. The best-fitting
model (Table 7) included age, PC4, and PC8 scores.
BCRS for girls in the 75th percentile of PC4 or PC8
scores are expected to be about 0.017 or 0.014 lower in
BCRC than for girls in the 25th percentile, respectively.
Discussion
Using PCA of visible and near-infra-red (NIR) spectra
from breast tissue, we were able to capture over 99% of
the variation in breast tissue optical properties through
eight PCs. Unlike the linear increase with age and BMI,
OS components had distinct patterns by TS suggesting
that OS can be used to objectively identify breast TS.
During early-stage breast development, the majority of
the optical information pertains to the skin, subcutane-
ous tissue including the adipose tissue and the pectoral
muscle, whereas for the later TS the optical signal of the
pectoral muscle is replaced by the actual breast tissue.
Fig. 1 Accuracy of the predictor determined by receiver operator
characteristic curve
Table 6 Breast cancer risk score (BCRS): simple and multivariate
regression results
Predictor Regression coefficient CI (95%) P value
Simple regression analysis
Age 0.004 −0.002 0.011 0.2001
BMI −0.0004 −0.0035 0.0026 0.7677
PC1 −0.002 −0.012 0.009 0.7526
PC2 −0.006 −0.012 0.001 0.4779
PC3 0.004 −0.009 0.017 0.5611
PC4 −0.015 −0.028 −0.001 0.0328
PC5 0.010 −0.002 0.023 0.0907
PC6 0.002 −0.009 0.014 0.7141
PC7 −0.001 −0.013 0.012 0.8963
PC8 −0.015 −0.026 −0.004 0.0082
Multiple regression analysis (best model by AIC)
PC4 −0.011 −0.025 0.002 0.0969
PC5 0.009 −0.003 0.020 0.1480
PC8 −0.015 −0.026 −0.004 0.0076
BMI body mass index, PC principal component, AIC Akaike’s information criteria
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The PC scores that are correlated with each stage are
sufficient to capture the changing ratios of muscle to
adipose to glandular tissue within the optically sampled
volume in girls’ chests during puberty.
Spectroscopically, the most striking features in the PC
spectra are the strong peaks at 930 nm and 970 nm repre-
senting lipid and water absorption, respectively. These
peaks both appear inversely in PC1 and are visible in PC2,
PC3, PC5, and PC6, and are not statistically significant,
reflecting a change in the adipose (lipid) and proliferating
glandular (water) tissue. While the spectral components
of the main tissue chromophores are overlapping (see
Additional file 1: Figure S1C), the short wavelength range
is dominated by the hemoglobins, whereas the long wave-
length range is affected by collagen [26].
The current PCA analysis, while being somewhat diffi-
cult to visualize, nevertheless provides strong evidence
of the ability to stage breast development in an objective
manner. Each of the current PCs carries information on
the various tissue chromophores as shown in Additional
file 2: Table S3. The final separation of the chromophores
requires significant additional computation. As Additional
file 2: Table S3 illustrates, the separate PCs are related to a
set of chromophores but it is the direction of these rela-
tionships and the strengths of these associations that
change as the breast develops. In Additional file 2: Table
S3, we show the correlation and the P values for PC1–8
and each chromophore. PC1, which accounts for the
greatest variation, is dominated by the overall attenuation
rather than the contributions of specific chromophores.
The other components, however, reveal how there is
additional adipose and dense tissue as the breast develops,
that the ratio between the two changes, and that there is
less signal from the pectoral muscle.
For example, PC2 scores are related to the amount of
dense tissue which increases as the breast matures from
TS2 to TS4. For transition from TS1 to TS2, which is the
onset of breast development, PC3 scores become positive
and remain positive through TS4, signaling an increase in
lipids or adipose tissue as the breast develops. Thus, the
onset of breast development is marked by an increase in
adipose tissue. In addition, the PC3 scores have a large
negative component at shorter wavelengths, indicating a
reduction in hemoglobin and/or myoglobin within the op-
tical measured tissue volume, indicating breast tissue with
lower relative blood volume and less contribution from the
pectoral muscle compared to TS1 (see Additional file 2:
Table S3). The increased relative absorption by lipids at the
expense of water and hence glandular tissue is also present,
as shown by the declining contribution of the PC2 scores.
Transition to T3 was also marked by an increase in PC6
scores, reflecting additional lipid content and an increase
in PC7 scores reflecting lower collagen.
Interestingly, although PC4 and PC5 scores did not map
clearly to TS they were different by BCRS. As Additional
file 2: Table S3 reveals, high PC4 scores indicate increased
collagen in the optically measured tissue volume and
decreased hemoglobin content and oxygenation and high
PC5 scores indicate less lipid.
We identified OS-derived principal components (PC2,
PC3, PC6, and PC 7) that mapped to breast developmental
stage. In particular, the complementarity of spectral fea-
tures in PC2 and PC6 and the unique short wavelength
absorption in PC3 are sufficient to capture the changing
ratio of muscle to adipose to glandular tissue in girls’ chests
during puberty, as noted by the multivariate regression
results (Tables 3, 4, and 5) and the variable importance
random forest plots (Additional file 1: Figures S4A-B).
Thus, this preliminary study suggests that OS-derived
measures have the potential to predict breast developmen-
tal stage in preteen and teen girls.
Furthermore, three OS-derived principal components
(PC4, PC5, and PC8 scores) together best predicted BCRS.
The PC4 and PC8 scores correlated negatively and signifi-
cantly with BCRS indicating that those with higher scores
in these variables tend to come from BCFH- families. The
PC5 scores positively correlated with BCRS implying that
those with higher scores in these variables tend to come
from BCFH+ families. It is of interest that the lipid-water
ratio, previously identified as a breast cancer risk factor in
adult women is not prominent in these spectra, but there
is strong absorption at the short wavelengths and long
wavelengths beyond 970 nm; this suggests that the relative
hemoglobin and collagen contributions may play a role in
BCFH status.
Table 7 Breast cancer risk score (BCRS): simple and multivariate
regression results in the late (TS3 − TS5) subgroup
Predictor Regression coefficient CI (95%) P value
Simple regression analysis
Age 0.007 −0.001 0.016 0.0849
BMI 0.001 −0.003 0.004 0.7802
PC1 −0.004 −0.016 0.009 0.5450
PC2 −0.006 −0.030 0.019 0.6447
PC3 −0.0003 −0.0183 0.0177 0.9708
PC4 −0.020 −0.035 −0.006 0.0074
PC5 0.010 −0.005 0.025 0.1697
PC6 −0.005 −0.021 0.010 0.5014
PC7 0.007 −0.010 0.024 0.4013
PC8 −0.021 −0.037 −0.005 0.0114
Multiple regression analysis (best model by AIC)
Age 0.007 −0.001 0.015 0.0802
PC4 −0.017 −0.032 −0.003 0.0211
PC8 −0.014 −0.030 0.002 0.0889
TS Tanner stage, BMI body mass index, BCRS breast cancer risk score, PC
principal component, AIC Akaike’s information criteria
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Conclusions
We have found that a non-invasive imaging method can
be used to accurately classify girls by breast developmental
stage. As the onset of breast development and the duration
in each stage may map to increased breast cancer sus-
ceptibility, studies of pubertal development can use
objective OS imaging methods, either alone or in combin-
ation with more subjective measures of breast development
based on maternal or self-report of breast development
stages, to more accurately predict breast development
changes over time.
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